Interception of cocaine by enzyme or antibody delivered with viral gene transfer: A novel strategy for preventing relapse in recovering drug users

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 8, 2011, Pages 880-891

  Brimijoin, Stephen ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Adeno associated viral vector; Butyrylcholinesterase; Cocaine hydrolase; Cocaine vaccine; Gene therapy; Helper dependent viral vector; Monoclonal antibody

Indexed keywords

AMPHETAMINE; ANTIBODY; CHOLERA TOXIN; CHOLINESTERASE; COCAINE; CYTOCHROME P450; ENZYME; GENOMIC DNA; HEMOCYANIN; HYDROLASE; IMMUNOGLOBULIN G; MACROGOL; MONOCLONAL ANTIBODY; NORCOCAINE; TETANUS TOXIN; VACCINE; VIRUS DNA; VIRUS VECTOR;

ABSTINENCE; ADENO ASSOCIATED VIRUS; BINDING AFFINITY; COCAINE DEPENDENCE; COMPLEX FORMATION; DOSE RESPONSE; DRUG HALF LIFE; DRUG SAFETY; DRUG SEEKING BEHAVIOR; DRUG UPTAKE; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME THERAPY; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; LIVER CELL; LIVER TOXICITY; LOCOMOTION; NONHUMAN; PROTEIN EXPRESSION; RELAPSE; REVIEW; REWARD; RISK BENEFIT ANALYSIS; TRANSGENE; TREATMENT RESPONSE; VACCINATION; VIRAL GENE DELIVERY SYSTEM;

EID: 84857696691     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711799219398     Document Type: Review

References (106)

1. Hatsukami, D.K.; Jorenby, D.E.; Gonzales, D.; Rigotti, N.A.; Glover, E.D.; Oncken, C.A.; Tashkin, D.P.; Reus, V.I.; Akhavain, R.C.; Fahim, R.E.; Kessler, P.D.; Niknian, M.; Kalnik, M.W.; Rennard, S.I. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin. Pharmacol. Ther., 2011, 89, 392-399.
2. Hatsukami, D.K.; Rennard, S.; Jorenby, D.; Fiore, M.; Koopmeiners, J.; de Vos, A.; Horwith, G.; Pentel, P.R. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther., 2005, 78, 456-467.
3. Pentel, P.R.; Malin, D.H.; Ennifar, S.; Hieda, Y.; Keyler, D.E.; Lake, J.R.; Milstein, J.R.; Basham, L.E.; Coy, R.T.; Moon, J.W.; Naso, R.; Fattom, A. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav., 2000, 65, 191-198.
4. Kosten, T.; Owens, S.M. Immunotherapy for the treatment of drug abuse. Pharmacol. Ther., 2005, 108, 76-85.
5. Kosten, T.R.; Rosen, M.; Bond, J.; Settles, M.; Roberts, J.S.; Shields, J.; Jack, L.; Fox, B. Human therapeutic cocaine vaccine, safety and immunogenicity. Vaccine, 2002, 20, 1196-1204.
6. Orson, F.M.; Kinsey, B.M.; Singh, R.A.; Wu, Y.; Kosten, T.R. Vaccines for cocaine abuse. Hum. Vaccin., 2009, 5.
7. Kinsey, B.M.; Jackson, D.C.; Orson, F.M. Anti-drug vaccines to treat substance abuse. Immunol. Cell Biol., 2009, 87, 309-314.
8. Hicks, M.J.; De BP, Rosenberg JB, Davidson JT, Moreno AY, Janda KD, Wee, S.; Koob, G.F.; Hackett, N.R.; Kaminsky, S.M.; Worgall, S.; Toth, M.; Mezey, J.G.; Crystal, R.G. Cocaine Analog Coupled to Disrupted Adenovirus, A Vaccine Strategy to Evoke High-titer Immunity Against Addictive Drugs. Mol. Ther., 2011, 19(3), 612-619.
9. Martell, B.A.; Mitchell, E.; Poling, J.; Gonsai, K.; Kosten, T.R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol. Psychiatry, 2005, 58, 158-164.
10. Carrera, M.R.; Ashley, J.A.; Zhou, B.; Wirsching, P.; Koob, G.F.; Janda, K.D. Cocaine vaccines, antibody protection against relapse in a rat model. Proc. Natl. Acad. Sci. USA, 2000, 97, 6202-6206.
11. Orson, F.M.; Kinsey, B.M.; Singh, R.A.; Wu, Y.; Gardner, T.; Kosten, T.R. The future of vaccines in the management of addictive disorders. Curr. Psychiatry Rep., 2007, 9, 381-387.
12. Martell, B.A.; Orson, F.M.; Poling, J.; Mitchell, E.; Rossen, R.D.; Gardner, T.; Kosten, T.R. Arch. Gen. Psychiatry, 2009, 66, 1116-1123.
13. Orson, F.M.; Kinsey, B.M.; Singh, R.A.; Wu, Y.; Gardner, T.; Kosten, T.R. Substance abuse vaccines. Ann. NY Acad. Sci., 2008, 1141, 257-269.
14. Gao, Y.; Orson, F.M.; Kinsey, B.; Kosten, T.; Brimijoin, S. The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chem. Biol. Interact., 2010, 187, 421-424.
15. Johnson, M.W.; Ettinger, R.H. Active cocaine immunization attenuates the discriminative properties of cocaine. Exp. Clin. Psychopharmacol., 2000, 8, 163-167.
16. Kantak, K.M.; Collins, S.L.; Lipman, E.G.; Bond, J.; Giovanoni, K.; Fox, B.S. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl.), 2000, 148, 251-262.
17. Haney, M.; Kosten, T.R. Therapeutic vaccines for substance dependence. Expert Rev. Vaccines, 2004, 3, 11-18.
18. Wee, S.; Hicks, M.J.; De, B.P.; Rosenberg, J.B.; Moreno, A.Y.; Kaminsky, S.M.; Janda, K.D.; Crystal, R.G.; Koob, G.F. Novel Cocaine Vaccine Linked to a Disrupted Adenovirus Gene Transfer Vector Blocks Cocaine Psychostimulant and Reinforcing Effects. Neuropsychopharmacology, 2011, [Epub ahead of print].
19. Redwan, R.M.; Larsen, N.A.; Zhou, B.; Wirsching, P.; Janda, K.D.; Wilson, I.A. Expression and characterization of a humanized cocaine-binding antibody. Biotechnol. Bioeng., 2003, 82, 612-618.
20. Norman, A.; Norman, M.K.; Buesing, W.R.; Tabet, M.R.; Tsibulsky, V.L.; Ball, W.J. The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. J. Pharmacol. Exp. Ther., 2009, 328, 873-881.
21. Norman, A.B.; Tabet, M.R.; Norman, M.K.; Buesing, W.R.; Pesce, A.J.; Ball, W.J. A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. J. Pharmacol. Exp. Ther., 2007, 320, 145-153.
22. Landry, D.W.; Zhao, K.; Yang, G.X.; Glickman, M.; Georgiadis, T.M. Antibody-catalyzed degradation of cocaine. Science, 1993, 259, 1899-1901.
23. Pan, Y.; Gao, D.; Zhan, C.G. Modeling the catalysis of anti-cocaine catalytic antibody, competing reaction pathways and free energy barriers. J. Am. Chem. Soc., 2008, 130, 5140-5149.
24. Cashman, J.R.; Berkman, C.E.; Underiner, G.E. Catalytic antibodies that hydrolyze (-)-cocaine obtained by a high-throughput procedure. J. Pharmacol. Exp. Ther., 2000, 293, 952-961.
25. Larsen, N.A.; de Prada, P.; Deng, S.X.; Mittal, A.; Braskett, M.; Zhu, X.; Wilson, I.A.; Landry, D.W. Crystallographic and biochemical analysis of cocaine-degrading antibody 15A10. Biochemistry, 2004, 43, 8067-8076.
26. Mets, B.; Winger, G.; Cabrera, C.; Seo, S.; Jamdar, S.; Yang, G.; Zhao, K.; Briscoe, R.J.; Almonte, R.; Woods, J.H.; Landry, D.W. A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc. Natl. Acad. Sci. USA, 1998, 95, 10176-10181.
27. Fang, J.; Qian, J.J.; Yi, S.; Harding, T.C.; Tu, G.H.; VanRoey, M.; Jooss, K. Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol., 2005, 23, 584-590.
28. Misra, A.L.; Giri, V.V.; Patel, M.N.; Alluri, V.R.; Mule, S.J. Disposition and metabolism of [3H] cocaine in acutely and chronically treated monkeys. Drug Alcohol Depend., 1977, 2, 261-272.
29. Ndikum-Moffor, F.M.; Schoeb, T.R.; Roberts, S.M. Liver toxicity from norcocaine nitroxide, an N-oxidative metabolite of cocaine. J. Pharmacol. Exp. Ther., 1998, 284, 413-419.
30. Brzezinski, M.R.; Abraham, T.L.; Stone, C.L.; Dean, R.A.; Bosron, W.F. Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine. Biochem. Pharmacol., 1994, 48, 1747-1755.
31. Brzezinski, M.R.; Spink, B.J.; Dean, R.A.; Berkman, C.E.; Cashman, J.R.; Bosron, W.F. Human liver carboxylesterase hCE-1, binding specificity for cocaine, heroin, and their metabolites and analogs. Drug Metab. Dispos., 1997, 25, 1089-1096.
32. Schuelke, G.S.; Konkol, R.J.; Terry, L.C.; Madden, J.A. Effect of cocaine metabolites on behavior, possible neuroendocrine mechanisms. Brain Res. Bull., 1996, 39, 43-48.
33. Morishima, H.O.; Whittington, R.A.; Iso, A.; Cooper, T.B. The comparative toxicity of cocaine and its metabolites in conscious rats. Anesthesiology, 1999, 90, 1684-1690.
34. Inaba, T.; Stewart, D.; Kalow, W. Metabolism of cocaine in man. Clin. Pharmacol. Ther., 1978, 23, 547-552.
35. Stewart, D.J.; Inaba, T.; Tang, B.K.; Kalow, W. Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci., 1977, 20, 1557-1564.
36. Duysen, E.G.; Li, B.; Darvesh, S.; Lockridge, O. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Toxicology, 2007, 233, 60-69.
37. Gorelick, D.A. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend., 1997, 48, 159-165.
38. Koetzner, L.; Woods, J.H. Characterization of butyrylcholinesterase antagonism of cocaine-induced hyperactivity. Drug Metab. Dispos., 2002, 30, 716-723.
39. Bresler, M.M.; Rosser, S.J.; Basran, A.; Bruce, N.C. Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1. Appl. Environ. Microbiol., 2000, 66, 904-908.
40. Turner, J.M.; Larsen, N.A.; Basran, A.; Barbas, C.F. 3rd.; Bruce, N.C.; Wilson, I.A.; Lerner, R.A. Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry, 2002, 41, 12297-12307.
41. Cooper, Z.D.; Narasimhan, D.; Sunahara, R.K.; Mierrzejewski, P.; Jutkiewicz, E.M.; Larsen, N.A.; Wilson, I.A.; Landry, D.W.; Woods, J.H. Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol. Pharmacol., 2006, 70, 1885-1891.
42. Collins, G.T.; Brim, R.L.; Narasimhan, D.; Ko, M.C.; Sunahara, R.K.; Zhan, C.G.; Woods, J.H. Cocaine esterase prevents cocaineinduced toxicity and the ongoing intravenous self-administration of cocaine in rats. J. Pharmacol. Exp. Ther., 2009, 331, 445-455.
43. Collins, G.T.; Carey, K.A.; Narasimhan, D.; Nichols, J.; Berlin, A.A.; Lukacs, N.W.; Sunahara, R.K.; Woods, J.H.; Ko, M.C. Amelioration of the cardiovascular effects of cocaine in rhesus monkeys by a long-acting mutant form of cocaine esterase. Neuropsychopharmacology, 2011, 36, 1047-1059.
44. Xie, W.; Altamirano, C.V.; Bartels, C.F.; Speirs, R.J.; Cashman, J.R.; Lockridge, O. An improved cocaine hydrolase, the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol. Pharmacol., 1999, 55, 83-91.
45. Sun, H.; Shen, M.L.; Pang, Y.P.; Lockridge, O.; Brimijoin, S. Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. J. Pharmacol. Exp. Ther., 2002, 302, 710-716.
46. Sun, H.; El Yazal, J.; Lockridge, O.; Schopfer, L.M.; Brimijoin, S.; Pang, Y.P. Predicted Michaelis-Menten complexes of cocainebutyrylcholinesterase. Engineering effective butyrylcholinesterase mutants for cocaine detoxication. J. Biol. Chem., 2001, 276, 9330-9336.
47. Pan, Y.; Gao, D.; Yang, W.; Cho, H.; Zhan, C.G. Free energy perturbation (FEP) simulation on the transition states of cocaine hydrolysis catalyzed by human butyrylcholinesterase and its mutants. J. Am. Chem. Soc., 2007, 129, 13537-13543.
48. Yang, W.; Xue, L.; Fang, L.; Chen, X.; Zhan, C.G. Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine. Chem. Biol. Interact., 2010, 187, 148-152.
49. Xue, Y.; Steketee, J.D.; Rebec, G.V.; Sun, W. Activation of D(2) - like receptors in rat ventral tegmental area inhibits cocainereinstated drug-seeking behavior. Eur. J. Neurosci., 2011, 33(7), 1291-1298.
50. Xue, L.; Ko, M.C.; Tong, M.; Yang, W.; Hou, S.; Fang, L.; Liu, J.; Zheng, F.; Woods, J.H.; Tai, H.H.; Zhan, C.G. Design, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol. Pharmacol., 2011, 79, 290-297.
51. Sun, H.; Pang, Y.-P.; Lockridge, O.; Brimijoin, S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol. Pharmacol., 2002, 621, 220-224.
52. Gao, Y.; Brimijoin, S. An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J. Pharmacol. Exp. Ther., 2004, 310, 1046-1052.
53. Gao, Y.; LaFleur, D.; Shah, R.; Zhao, Q.; Singh, M.; Brimijoin, S. An albumin-butyrylcholinesterase for cocaine toxicity and addiction, catalytic and pharmacokinetic properties. Chem. Biol. Interact., 2008, 175, 83-87.
54. Brimijoin, S.; Gao, Y.; Anker, J.J.; Gliddon, L.A.; Lafleur, D.; Shah, R.; Zhao, Q.; Singh, M.; Carroll, M.E. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology, 2008, 33, 2715-2725.
55. Carroll, M.E.; Gao, Y.; Brimijoin, S.; Anker, J.J. Effects of cocaine hydrolase on cocaine self-administration under a PR schedule and during extended access (escalation) in rats. Psychopharmacology (Berl.), 2011, 213, 817-829.
56. Koob, G.; Kreek, M.J. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am. J. Psychiatry, 2007, 164, 1149-1159.
57. Abuchowski, A.; McCoy, J.R.; Palczuk, N.C.; van Es, T.; Davis, F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem., 1977, 252, 3582-3586.
58. Gao, Y.; Atanasova, E.; Sui, N.; Pancook, J.D.; Watkins, J.D.; Brimijoin, S. Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats. Mol. Pharmacol., 2005, 67, 204-211.
59. Papadakis, E.D.; Nicklin, S.A.; Baker, A.H.; White, S.J. Promoters and control elements, designing expression cassettes for gene therapy. Curr. Gene Ther., 2004, 4, 89-113.
60. Pancook, J.D.; Pecht, G.; Ader, M.; Mosko, M.; Lockridge, O.; Watkins, J.D. Application of directed evolution technology to optimize the cocaine hydrolase activity of human butyrylcholinesterase. FASEB J., 2003, 17, A565.
61. Parks, R.J.; Chen, L.; Anton, M.; Sankar, U.; Rudnicki, M.A.; Graham, F.L. A helper-dependent adenovirus vector system, removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA, 1996, 93, 13565-13570.
62. Gao, Y.; Brimijoin, S. Lasting reduction of cocaine action in neostriatum--a hydrolase gene therapy approach. J. Pharmacol. Exp. Ther., 2009, 330, 449-457.
63. Heffron, P.F. Actions of the selective inhibitor of cholinesterase tetramonoisopropyl pyrophosphortetramide on the rat phrenic nerve-diaphragm preparation. Br. J. Pharmacol., 1972, 46, 714-724.
64. Wise, R.A.; Kiyatkin, E.A. Differentiating the rapid actions of cocaine. Nat. Rev. Neurosci., 2011, 12, 479-484.
65. Scott, E.M. Inheritance of two types of deficiency of human serum cholinesterase. Ann. Hum. Genet., 1973, 37, 139-143.
66. Hodgkin, W.; Giblett, E.R.; Levine, H.; Bauer, W.; Motulsky, A.G. Complete pseudocholinesterase deficiency, genetic and immunologic characterization. J. Clin. Invest., 1965, 44, 486-493.
67. La Du, B.N.; Lockridge, O. Molecular biology of human serum cholinesterase. Fed. Proc., 1986, 45, 2965-2969.
68. Nachon, F.; Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J.C.; Lockridge, O. Engineering of a monomeric and lowglycosylated form of human butyrylcholinesterase, expression, purification, characterization and crystallization. Eur. J. Biochem., 2002, 269, 630-637.
69. Lockridge, O.; Eckerson, H.W.; La Du, B.N. Interchain disulfide bonds and subunit organization in human serum cholinesterase. J. Biol. Chem., 1979, 254, 8324-8330.
70. Lockridge, O.; Bartels, C.F.; Vaughan, T.A.; Wong, C.K.; Norton, S.E.; Johnson, L.L. Complete amino acid sequence of human serum cholinesterase. J. Biol. Chem., 1987, 262, 549-557.
71. Whittaker, M. Cholinesterase. Basel, Karger, 1986
72. Chatonnet, A.; Lockridge, O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J., 1989, 260, 625-634.
73. Saxena, A.; Sun, W.; Fedorko, J.M.; Koplovitz, I.; Doctor, B.P. Prophylaxis with human serum butyrylcholinesterase protects guinea pigs exposed to multiple lethal doses of soman or VX. Biochem. Pharmacol., 2011, 81, 164-169.
74. Saxena, A.; Sun, W.; Luo, C.; Doctor, B.P. Human serum butyrylcholinesterase, in vitro and in vivo stability, pharmacokinetics, and safety in mice. Chem. Biol. Interact., 2005, 157-158, 199-203.
75. Weber, A.; Butterweck, H.; Mais-Paul, U.; Teschner, W.; Lei, L.; Muchitsch, E.M.; Kolarich, D.; Altmann, F.; Ehrlich, H.J.; Schwarz, H.P. Biochemical, molecular and preclinical characterization of a double-virus-reduced human butyrylcholinesterase preparation designed for clinical use. Vox Sang, 2011, 100, 285-297.
76. Jozkowicz, A.; Dulak, J. Helper-dependent adenoviral vectors in experimental gene therapy. Acta Biochim. Pol., 2005, 52, 589-599.
77. Brunetti-Pierri, N.; Ng, P. Helper-dependent adenoviral vectors for liver-directed gene therapy. Hum. Mol. Genet., 2011, 20, R7-R13.
78. Vetrini, F.; Ng, P. Liver-directed gene therapy with helperdependent adenoviral vectors, current state of the art and future challenges. Curr. Pharm. Design, 2011, 17, 2488-2499.
79. Mingozzi, F.; High, K.A. Therapeutic in vivo gene transfer for genetic disease using AAV, progress and challenges. Nat. Rev. Genet., 2011, 12, 341-355.
80. Berns, K.I.; Hauswirth, W.W. Adeno-associated viruses. Adv. Virus Res., 1979, 25, 407-449.
81. Mitani, K.; Graham, F.L.; Caskey, C.T.; Kochanek, S. Rescue, propagation, and partial purification of a helper virus-dependentadenovirus vector. Proc. Natl. Acad. Sci. USA, 1995, 92, 3854-3858.
82. Kochanek, S.; Clemens, P.R.; Mitani, K.; Chen, H.H.; Chan, S.; Caskey, C.T. A new adenoviral vector, Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. USA, 1996, 93, 5731-5736.
83. Morral, N.; O'Neal, W.; Rice, K.; Leland, M.; Kaplan, J.; Piedra, P.A.; Zhou, H.; Parks, R.J.; Velji, R.; Aguilar-Córdova, E.; Wadsworth, S.; Graham, F.L.; Kochanek, S.; Carey, K.D.; Beaudet, A.L. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liverdirected gene transfer in baboons. Proc. Natl. Acad. Sci. USA, 1999, 96, 12816-12821.
84. Kim, I.H.; Jozkowicz, A.; Piedra, P.A.; Oka, K.; Chan, L. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc. Natl. Acad. Sci. USA, 2001, 98, 13282-13287.
85. Muruve, D.A. The innate immune response to adenovirus vectors. Hum. Gene Ther., 2004, 15, 1157-1166.
86. Brunetti-Pierri, N.; Palmer, D.J.; Beaudet, A.L.; Carey, K.D.; Finegold, M.; Ng, P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene Ther., 2004, 15, 35-46.
87. Raper, S.E.; Chirmule, N.; Lee, F.S.; Wivel, N.A.; Bagg, A.; Gao, G.P.; Wilson, J.M.; Batshaw, M.L. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab., 2003, 80, 148-158.
88. Seregin, S.S.; Appledorn, D.M.; McBride, A.J.; Schuldt, N.J.; Aldhamen, Y.A.; Voss, T.; Wei, J.; Bujold, M.; Nance, W.; Godbehere, S.; Amalfitano, A. Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol. Ther., 2009, 17, 685-696.
89. Dong, J.Y.; Fan, P.D.; Frizzell, R.A. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther., 1996, 7, 2101-2112.
90. Kaplitt, M.G.; Leone, P.; Samulski, R.J.; Xiao, X; Pfaff, D.W.; O'Malley, K.L.; During, M.J. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet., 1994, 8, 148-154.
91. Koornneef, A.; Maczuga, P.; van Logtenstein, R.; Borel, F.; Blits, B.; Ritsema, T.; van Deventer, S.; Petry, H.; Konstantinova, P. Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice. Mol. Ther., 2011, 19, 731-740.
92. Choi, S.H.; Lee, H.C. Long-term, antidiabetogenic effects of GLP-1 gene therapy using a double-stranded, adeno-associated viral vector. Gene Ther., 2011, 18, 155-163.
93. Brantly, M.L.; Chulay, J.D.; Wang, L.; Mueller, C.; Humphries, M.; Spencer, L.T.; Rouhani, F.; Conlon, T.J.; Calcedo, R.; Betts, M.R.; Spencer, C.; Byrne, B.J.; Wilson, J.M.; Flotte, T.R. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl. Acad. Sci. USA, 2009, 106, 16363-16368.
94. Manno, C.S.; Pierce, G.F.; Arruda, V.R.; Glader, B.; Ragni, M.; Rasko, J.J.; Ozelo, M.C.; Hoots, K.; Blatt, P.; Konkle, B.; Dake, M.; Kaye, R.; Razavi, M.; Zajko, A.; Zehnder, J.; Rustagi, P.K.; Nakai, H.; Chew, A.; Leonard, D.; Wright, J.F.; Lessard, R.R.; Sommer, J.M.; Tigges, M.; Sabatino, D.; Luk, A.; Jiang, H.; Mingozzi, F.; Couto, L.; Ertl, H.C.; High, K.A.; Kay, M.A. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 2006, 12, 342-347.
95. Wagner, J.A.; Messner, A.H.; Moran, M.L.; Daifuku, R.; Kouyama, K.; Desch, J.K.; Manley, S.; Norbash, A.M.; Conrad, C.K.; Friborg, S.; Reynolds, T.; Guggino, W.B.; Moss, R.B.; Carter, B.J.; Wine, J.J.; Flotte, T.R.; Gardner, P. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope, 1999, 109, 266-274.
96. Christine, C.W.; Starr, P.A.; Larson, P.S.; Eberling, J.L.; Jagust, W.J.; Hawkins, R.A.; VanBrocklin, H.F.; Wright, J.F.; Bankiewicz, K.S.; Aminoff, M.J. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology, 2009, 73, 1662-1669.
97. Jaski, B.E.; Jessup, M.L.; Mancini, D.M.; Cappola, T.P.; Pauly, D.F.; Greenberg, B.; Borow, K.; Dittrich, H.; Zsebo, K.M.; Hajjar, R.J.; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J. Card. Fail., 2009, 15, 171-181.
98. Mease, P.J.; Wei, N.; Fudman, E.J.; Kivitz, A.J.; Schechtman, J.; Trapp, R.G.; Hobbs, K.F.; Greenwald, M.; Hou, A.; Bookbinder, S.A.; Graham, G.E.; Wiesenhutter, C.W.; Willis, L.; Ruderman, E.M.; Forstot, J.Z.; Maricic, M.J.; Dao, K.H.; Pritchard, C.H.; Fiske, D.N.; Burch, F.X.; Prupas, H.M.; Anklesaria, P.; Heald, A.E. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene, results of a phase 1/2 Study. J. Rheumatol., 2010, 37, 692-703.
99. McCarty, D.M.; Fu, H.; Monahan, P.E.; Toulson, C.E.; Naik, P.; Samulski, R.J. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther., 2003, 10, 2112-2118.
100. Michelfelder, S.; Trepel, M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv. Genet., 2009, 67, 29-60.
101. Gill, D.R.; Pringle, I.A.; Hyde, S.C. Progress and prospects, the design and production of plasmid vectors. Gene Ther., 2009, 16, 165-171.
102. Dorer, D.E.; Nettelbeck, D.M. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv. Drug Deliv. Rev., 2009, 61, 554-571.
103. Leevy, C.M.; Mendenhall, C.L.; Lesko, W.; Howard, M.M. Estimation of hepatic blood flow with indocyanine green. J. Clin. Invest., 1962, 41, 1169-1179.
104. Kreppel, F.; Kochanek, S. Long-term transgene expression in proliferating cells mediated by episomally maintained highcapacity adenovirus vectors. J. Virol., 2004, 78, 9-22.
105. Kuntz, E.; Kuntz, H.-D.; Ed. Hepatology, Textbook and Atlas, History, Morphology, Biochemistry, Diagnostics, Clinic, Therapy. Heidelberg, New York, Springer, 2008.
106. Spalding, K.L.; Bhardwaj, R.D.; Buchholz, B.A.; Druid, H.; Frisen, J. Retrospective birth dating of cells in humans. Cell, 2005, 122, 133-143.